All In Biotech

Drug Trial Radar · NCT07206043

Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers

Single-Center, Randomized, Cohort, Single-Blind, Comparative Clinical Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of RPH-104 in a New 80 mg/mL Dosage Form Following Single Subcutaneous and Intravenous Administration at Doses of 80 mg, 160 mg, and 320 mg in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

Dec 3, 2024

Primary completion

Feb 27, 2025

Study completion Jul 25, 2025

Sponsor

Lead sponsor
R-Pharm International, LLCIndustry
Sponsor type
Industry
Collaborators
LLC "Exacte Labs"; JSC "R-Pharm", Russia (R-Pharm Group)
First posted
Oct 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, immunogenicity and pharmacokinetics of RPH-104 after single intravenous and subcutaneous administration to healthy volunteers at different doses

Conditions

  • Healthy

Interventions

  • RPH-104 80 mgBiological

    solution for intravenous injection, 40 mg/mL

  • RPH-104 160 mgBiological

    solution for intravenous injection, 40 mg/mL

  • RPH-104 320 mgBiological

    solution for intravenous injection, 40 mg/mL

  • RPH-104 320 mgBiological

    solution for subcutaneous injection, 80 mg/mL

  • RPH-104 80 mgBiological

    solution for subcutaneous injection, 40 mg/mL

  • RPH-104 80 mgBiological

    solution for subcutaneous injection, 80 mg/mL

  • PlaceboDrug

    0.9% Sodium Chloride solution for Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The area under the plasma drug concentration-time curve (AUC) of RPH-104 from the moment of administration to infinity after a single injection of RPH-104Time frame: Up to day 61 ± 3
  2. The maximum concentration of RPH-104 in the blood serum after a single injection of RPH-104Time frame: Up to day 61 ± 3
  3. Percentage of volunteers (%) with AEs and SAEsTime frame: Up to day 61 ± 3
  4. Percentage of volunteers (%) with AEs ≥ Grade 3 according to CTCAE 5.0Time frame: Up to day 61 ± 3
  5. Percentage of volunteers (%) with ADRs and serious ADRsTime frame: Up to day 61 ± 3
  6. Percentage of volunteers (%) with ADRs ≥ Grade 3 according to CTCAE 5.0Time frame: Up to day 61 ± 3
  7. Percentage of volunteers (%), who prematurely discontinued participation in the study due to AE/SAE and ADR/serious ADRTime frame: Up to day 61 ± 3
  8. Percentage of volunteers (%) with AEs of special interestTime frame: Up to day 61 ± 3
  9. Percentage of volunteers (%), who developed binding antibodies to RPH-104Time frame: Up to day 61 ± 3
  10. Percentage of volunteers (%), who developed neutralizing antibodies to RPH-104Time frame: Up to day 61 ± 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Llc "Research Lab"

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.